EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Margherita Rimini iD, Carles Fabregat-Franco, Mara Persano, Valentina Burgio, Francesca Bergamo, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer und 14 weitere

Targeted Oncology · 2023

DOI: 10.1007/s11523-022-00933-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2023. Verfasst von Margherita Rimini und 25 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS San Raffaele Scientific Institute Hospital, Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy. margherita.rimini@gmail.…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Isocitrate dehydrogenase-1 (IDH1) mutations occur in a significant proportion of intrahepatic cholangiocarcinomas (iCCAs). No data are available regarding the prognostic impact of IDH1 mutations in advanced iCCA patients after progression on first-line therapies. OBJECTIVE: We investigated the role of IDH1 mutation in advanced iCCA after progression on first-line therapies. PATIENTS AND METHODS: After progression on first-line therapies for advanced iCCA, consecutive patients were retrospectively collected. The IDH1 status was tested at baseline. This analysis aimed to examine the association between the presence of IDH1 missense mutations and survival outcomes in patients with advanced iCCA treated with a second-line therapy. RESULTS: The analysis included 119 patients; 56/119 (47%) were IDH1 mutated (IDH1m) and 63/119 (53%) were IDH1 wild type (IDH1 WT). At univariate analysis for overall survival (OS), the presence of IDH1 mutation was associated with a worse median OS (mOS; 8.2 vs. 14.1 months; hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.2-3.0, p = 0.0047). Patients harboring IDH1 mutations showed a worse objective response rate (ORR) compared with patients without IDH1 mutation, whereas no significant differences in disease control rate (DCR) were found. Multivariate analysis confirmed IDH1 mutations as an independent negative prognostic factor for OS (HR 1.7, 95% CI 1.1-2.7, p = 0.0256). By evaluating only patients receiving FOLFOX as second-line therapy, no statistically significant differences were found in terms of both OS and PFS between IDH1m and IDH1 WT patients. In this subset of patients, those harboring an IDH1 mutation showed a worse ORR and DCR compared with those without. Finally, at univariate analysis for OS from third-line treatment, the presence of an IDH1 mutation was associated with a trend toward a worse mOS (6.0 vs. 11.9 months; HR 1.6, 95% CI 0.8-3.2, p = 0.25). CONCLUSION: The present analysis constitutes the first evidence of a negative prognostic impact of IDH1 mutations in a cohort of patients treated after progression on first-line therapies in contrast to IDH1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsHumansRetrospective StudiesIsocitrate DehydrogenasePrognosisMutationBile Ducts, Intrahepatic

Substanzen

Isocitrate DehydrogenaseIDH1 protein, human

Autor:innen und Institutionen

  • IRCCS San Raffaele Scientific Institute Hospital, Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy. margherita.rimini@gmail.com.
  • Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Medical Oncology, University and University Hospital, Cagliari, Italy.
  • IRCCS San Raffaele Scientific Institute Hospital, Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy.
  • Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padua, Italy.
  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

ORCID-Profile: Margherita Rimini

Zitieren

APA

Rimini, M., Fabregat-Franco, C., Persano, M., Burgio, V., Bergamo, F., Niger, M., Scartozzi, M., Rapposelli, I. G., Aprile, G., Ratti, F., Pedica, F., Verdaguer, H., Rizzato, M., Nichetti, F., Lai, E., Cappetta, A., Macarulla, T., Fassan, M., De Braud, F., …, & Casadei-Gardini, A. (2023). Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients. Targeted Oncology. https://doi.org/10.1007/s11523-022-00933-7

Vancouver

Rimini M, Fabregat-Franco C, Persano M, Burgio V, Bergamo F, Niger M, et al. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients. Targeted Oncology. 2023. doi:10.1007/s11523-022-00933-7

BibTeX
@article{Rimini2023,
  author = {Rimini, Margherita and Fabregat-Franco, Carles and Persano, Mara and Burgio, Valentina and Bergamo, Francesca and Niger, Monica and Scartozzi, Mario and Rapposelli, Ilario Giovanni and Aprile, Giuseppe and Ratti, Francesca and Pedica, Federica and Verdaguer, Helena and Rizzato, Mario and Nichetti, Federico and Lai, Eleonora and Cappetta, Alessandro and Macarulla, Teresa and Fassan, Matteo and De Braud, Filippo and Pretta, Andrea and Simionato, Francesca and De Cobelli, Francesco and Aldrighetti, Luca and Fornaro, Lorenzo and Cascinu, Stefano and Casadei-Gardini, Andrea},
  title = {Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients},
  journal = {Targeted Oncology},
  year = {2023},
  doi = {10.1007/s11523-022-00933-7}
}
Kostenlos starten →